• 23-Jul-2018

  IOTA Pharmaceuticals featured in the Cambridge Independent newspaper

• 23-May-2018

  IOTA Pharmaceuticals announce the creation of a Glioblastoma Drug Bank to support and accelerate new research into brain cancer therapy

• 22-May-2018

  IOTA hosts BBSRC student

• 01-May-2018

  IOTA participates in the design of novel antiparasitic agents

• 27-Apr-2018

  IOTA scientist publishes on new machine-learning techniques for drug discovery

• 21-Feb-2018

  IOTA scientist in collaboration with Cambridge University publishes on methods to improve screening

• 11-Dec-2017

  IOTA scientists review the impact of phenotypic profiling in GBM drug discovery and patient stratification

• 07-Sep-2017

  IOTA Pharmaceuticals in £1.5M WINDOW Consortium tackling glioblastoma

• 21-Aug-2017

  IOTA scientists publish ACS Perspective on Fragment-Based Drug Discovery for Phosphodiesterases

• 14-Jul-2017

  IOTA scientist publishes book chapter on drug targeting for Protein-Protein Interactions

• 31-Jan-2017

  IOTA @ Fragments 2017

• 10-Oct-2016

  IOTA will be at the FBLD 2016 in Boston in October 2016

• 15-Jun-2016

  IOTA scientists publish paper on use of biosensor technology in PDE inhibitor binding characterization

• 14-Apr-2016

  PDE4NPD Consortium in collaboration with IOTA Pharmaceuticals announces PDE Toolbox for parasite drug discovery and PDE biology

• 20-Jan-2015

  IOTA publishes paper on the use of fragment based screening to discover novel drug hits for neglected parasitic diseases

• 18-Jul-2014

  IOTA publishes review with Genentech scientists describing the use of mechanism-informed phenotypic screening (MIPS) in oncology drug discovery

• 02-Apr-2014

  IOTA Pharmaceuticals in €7.8M consortium tackling neglected parasitic diseases 

• 14-Mar-2013

  IOTA publishes paper on virtual screening of T. brucei phosphodiesterase inhibitors

• 25-Oct-2012

  IOTA scientists publish on fragment based drug discovery for T. brucei phosphodiesterases

 Read more